Introduction
Ovarian cancer is the leading cause of gynecological cancer death in women in the United States, causing an estimated 13,850 deaths in 2010 [1] . Unfortunately, due to the absence of detectable symptoms in the early stage of the disease and a lack of an effective screening method, approximately 75% of women with ovarian cancer present with stage III and IV [2] . The 5-year relative survival rate of ovary cancer patients is 89.3% and 65.5% for stage I and II, respectively, whereas the rate is only 33.5% and 17.9% for stage III and IV, respectively [3] . In the last two decades, Vol. 56, No. 1, 2013 only stage I and II patients showed improvement in cure rate. In contrast, stage III and IV patients showed prolongation in survival time but no improvement in survival rate [4] . Age, performance status, stage of the disease at diagnosis, extent of cytoreductive surgery and residual disease are important independent prognostic factors for survival [5, 6] .
Many researchers have investigated whether the CA-125 level can be correlated to cancer relapse and survival in various clinical situations. Lower levels at completion of primary therapy [7] , lower levels prior to maintenance therapy [8] , early changes during maintenance therapy [9] and early normalization during primary chemotherapy [10] could predict positive tumor response and longer survival. In addition, nadir levels of serum CA-125 during primary chemotherapy could predict the risk of tumor recurrence [11, 12] .
Markman et al. [13] reported that early changes in CA-125 levels are an independent prognostic factor of survival. In their study, patients who achieved normalization of serum CA-125 levels (<35 U/mL) after the second cycle of platinum-based chemotherapy had significant improvement in median survival compared with those with serum CA-125>35 U/mL. Rocconi et al. [10] compared patients who achieved normalization of CA-125 by the third cycle of chemotherapy with patients who failed to achieve normalization by the third cycle. Patients with early normalization demonstrated improved progression free survival (PFS), overall survival (OS) and platinum sensitivity.
Recently, it has been suggested that nadir serum CA-125 levels are independently associated with PFS in patients with complete remission after first-line therapy in ovarian cancer [11, 12, 14] . The optimal cut-off value of serum CA-125 to predict recurrence varied, ranging from 10 to 25 U/mL.
Because there are no reports about the value of serum CA-125 levels in patients with advanced epithelial ovarian cancer with complete remission after chemotherapy with paclitaxel (175 mg/ m2) and carboplatin (area under the curve of 5) every 3 weeks for a total of six cycles, we analyzed the value of serum CA-125 levels in this study. Following initial eligibility screening, the following inclusion criteria were applied to determine the final study population: 1) elevated (≥ 35 U/mL) serum CA-125 level at the time of diagnosis, 2) histologic documentation of epithelial ovarian cancer, 3) stage of disease III (A, B, and C) and IV treated with primary cytoreductive surgery and postoperative chemotherapy, 4) complete clinical and radiographic response to initial treatment with normalization of CA-125 (<35 U/mL), 5) follow-up serum CA-125 determinations and/or radiographic scans at 1-to 3 -month intervals, and 6) clinical and radiographic determination of disease status at the time of last follow-up or recurrence.
Materials and Methods
After primary surgical staging procedure, all patients received combination chemotherapy with paclitaxel (175 mg/m 2 by 3 hour infusion) and carboplatin (area under the curve of 5) every 3 weeks for a total of six cycles. The treatment response was assessed by a complete history, physical examination, appropriate imaging studies (chest X-ray, computed tomography, magnetic resonance imaging and positron emission tomography) and serum CA-125 level. Serum CA-125 levels were measured preoperatively and within 1 week before each cycle of primary adjuvant chemotherapy. All serum samples were analyzed in the same laboratory at CNUH. Optimal cytoreductive surgery was defined as a following review of the surgery and pathology report <1 cm of residual disease was present (following the recommendations of the Gynecology Oncology Group Protocol 17). Complete response was defined as the absence of all measurable disease for at least 4 weeks and the normalization of the serum CA-125 level. Step-wise regression techniques were used to build multivariate models using a significance level of 0.10 to remain in the model. The differences in OS and PFS by nadir serum CA-125 levels and normalization timing were evaluated using the Kaplan-Meier method with log-rank tests. Statistical analyses were performed using SPSS ver.17.0 (SPSS Inc., Chicago, IL, USA). All P-values reported are two-sided, and a P-value <0.05 was considered statistically significant.
Statistical analyses

Results
The characteristics of the patients are summarized in Table 1 . In the entire study population, the median value of the nadir serum CA-125 level was 10.2 U/mL (range, 0.75 to 34.9 U/mL). The nadir CA-125 level was categorized into two groups: group A, ≤10 U/mL (n=56, 46.7% of total) and group B, 10 to 35 U/mL. The median age, body mass index, tumor stage, tumor histology, tumor grade, distribution of residual tumor size, peritoneal cytology and initial serum CA-125 level were not statistically different between the groups. We evaluated the potential correlation between the residual tumor size and the nadir CA-125 level; non-significant correlation was evident (Table 2) . We also tested the correlation between initial serum CA-125 level and the nadir CA-125 level, but it also showed non-significant correlation (P=0.368) ( Table 2 ).
The median PFS in group A was 21.6 months (95% confidence interval [CI], 14.0 to 29.2) and in group B was 12.5 months (95% CI, 10.5 to 14.5) (log-rank test, P=0.0047) (Fig. 1) (Fig. 2) . In the multivariate Cox regression model, the hazards ratio was adjusted for covariates. PFS was significantly associated with nonserous histology and residual tumor size >1.0 cm (P=0.013 and P =0.03, respectively) ( Table 3 ). Other variables, such as tumor stage, grade and age at the time of diagnosis were not significantly associated with PFS.
The serum CA-125 levels after surgery and after each of the three cycles of adjuvant chemotherapy were significantly higher in the recurrent group compared with the non-recurrent group (P=0.037, P<0.001, P=0.003, and P=0.032; respectively). ROC curves after surgery and after each of the three cycles of adjuvant chemotherapy revealed that the most significant factor to predict recurrence was serum CA-125 level following the 1st cycle of chemotherapy (area under curve=0.684, P=0.02) ( Table 4 ). The optimal cut point on the ROC curve of serum CA-125 level after 1st cycle of chemotherapy closest to the left upper corner corresponded to a threshold serum CA-125 level of 35 U/mL. At this cut point, the serum CA-125 level after the 1st cycle of adjuvant chemotherapy was able to predict disease progression with a sensitivity of 79.7% and a specificity of 61.0%. The median PFS was 64.6 months (95% CI, 13.9 to 115.2) and 12.8 months (95% CI, 11.8 to 13.8) in patients with serum CA-125 levels ≤35 U/mL and >35 U/mL after he 1st cycle of adjuvant chemotherapy, respectively (log-rank test, P=0.0001). Median value of preoperative CA-125 in this study group was 636.8 U/mL. The median PFS and OS were not statistically different between the patients with preoperative CA-125 levels ≥636.8 U/mL and patients with values exceeding 636.8 U/mL (log-rank test, P=0.719 and P=0.316; respectively).
Discussion
The serum CA-125 level is elevated most consistently in advanced epithelial ovarian cancer, and its value has been demonstrated as a marker for patient prognosis, disease progression and response to chemotherapy. The nadir CA-125 is defined as lowest point reached during treatment. Recently, some researchers reported the prognostic value of nadir CA-125 in advanced epithelial ovarian cancer [11, 12, [14] [15] [16] . The optimal cutoff level of the nadir CA-125 to predict PFS varies from 10 to 25 U/mL. There has been no unified consensus about the fixed cut-off nadir value for CA-125.
In this study, we analyzed serum CA-125 levels in patients who achieved complete remission after primary adjuvant chemotherapy in advanced epithelial ovarian cancer. The median nadir CA-125 level in our subjects was 10.18 U/mL. PFS and OS showed significant differences between patients with nadir CA-125 ≤10 U/ mL and 10 to 35 U/mL. Similar to a recent study [15] , our data revealed that serum CA-125 in patients with advanced epithelial ovarian cancer with complete remission after primary adjuvant chemotherapy is an independent prognostic factor.
Previous studies reported the timing of normalization of CA-125 correlates to survival. Markman et al. [13] reported that early changes in the serum CA-125 level 8 weeks after initiation therapy was a significant prognostic factor on OS in advanced ovarian cancer. Rocconi et al. [10] found that the timing of normalization of CA-125 throughout primary treatment confirmed the aforementioned findings and corresponded to survival, especially in the 3rd cycle of chemotherapy as a clinically useful parameter for response to current therapy. But, there has been little consensus concerning the timing and which level of serum CA-125 is more effective to predict the recurrence. In our study, we analyzed comparison of series serum CA-125 between the recurrent and non-recurrent groups during primary adjuvant chemotherapy. Serum CA-125 levels after surgery and after the 1st, 2nd, and 3rd cycles of adjuvant chemotherapy were significantly higher in the recurrent group compared to the non-recurrent group. The ROC curve yield for estimating the prognostic value of each cycle of CA-125 revealed 
